CVS Health's Fourth Quarter Performance Surpasses Expectations, Reinforcing 2026 Profit Outlook
CVS Health, a leading healthcare provider, reported impressive fourth-quarter earnings and revenue, surpassing analysts' estimates. This achievement marks a significant milestone in the company's turnaround strategy, as it reaffirms the 2026 profit guidance that initially impressed investors. The CEO, David Joyner, who took office in late 2024, has been instrumental in driving this positive trajectory.
CVS CFO Brian Newman attributed the company's success to a challenging 2024, followed by a successful 2025. He highlighted a full-year profit range of $7 to $7.20 per share, aligning with analysts' expectations of $7.17 per share. Additionally, CVS is maintaining its 2026 revenue guidance of at least $400 billion, although the actual figures may be influenced by various headwinds.
One significant factor is the company's decision to exit the Affordable Care Act individual exchange market, which contributes to approximately $20 billion in headwinds. This move is part of a broader strategy to address lower drug prices resulting from President Donald Trump's deals with pharmaceutical companies. CVS is also accepting discount cards from TrumpRx, the president's direct-to-consumer platform, for eligible patients, demonstrating a commitment to cost reduction.
CVS's turnaround plan is multifaceted. The company anticipates growth in 2025, driven by the Aetna insurance business and Caremark, its pharmacy benefit manager. Oak Street Health, a primary-care provider, is also expected to improve profitability after strategic closures. The retail pharmacy business benefits from technological investments, new locations, and customers acquired from Rite Aid's bankruptcy.
The fourth-quarter financial results showcased CVS's resilience. The company reported net income of $2.92 billion, or $2.30 per share, a significant improvement from the previous year. Excluding certain items, adjusted earnings reached $1.09 per share. Revenue increased by 8.2% to $105.69 billion, with all business segments contributing to this growth.
The insurance business, a key segment, generated $36.29 billion in revenue, a 10% increase. Medicare Advantage plans played a crucial role in this growth, with the unit on track to achieve target margins of 3% to 4% by 2028. Despite elevated medical costs, Aetna and other insurers are adapting to navigate this challenge.
CVS's pharmacy and consumer wellness division saw a 12.4% revenue increase to $37.66 billion, primarily due to higher prescription volume. However, pharmacy reimbursement pressure and generic drug market dynamics impacted this segment. The health services segment, including Caremark, generated $51.24 billion in revenue, a 9% increase, showcasing the company's diverse and robust operations.
In summary, CVS Health's fourth-quarter performance exceeds expectations, reinforcing its 2026 profit outlook. The company's strategic initiatives, led by CEO David Joyner, have positioned it for success, with a focus on cost reduction, business diversification, and operational excellence.
